Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease

• Published in: Nature communications Vol. 4; no. 1; p. 2735
• Main Authors: Ueki, Nobuhide, Lee, Siyeon, Sampson, Nicole S., Hayman, Michael J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 05.11.2013; Nature Publishing Group
• Subjects: 631/67/1059/602; 631/92/436/2388; 692/308/153; Animals; Antineoplastic Agents - therapeutic use; Cathepsin L - metabolism; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Enzymologic - physiology; Gene Expression Regulation, Neoplastic - physiology; Histone Deacetylases - metabolism; Humanities and Social Sciences; Humans; Mice; multidisciplinary; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - enzymology; Prodrugs; Puromycin - chemistry; Puromycin - metabolism; Puromycin - therapeutic use; Science; Science (multidisciplinary)

Eradication of cancer cells while minimizing damage to healthy cells is a primary goal of cancer therapy. Highly selective drugs are urgently needed. Here we demonstrate a new prodrug strategy for selective cancer therapy that utilizes increased histone deacetylase (HDAC) and tumour-associated prote...